214 related articles for article (PubMed ID: 12853452)
21. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis.
Hervio L; Durlach V; Girard-Globa A; Anglés-Cano E
Biochemistry; 1995 Oct; 34(41):13353-8. PubMed ID: 7577920
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
Stewart RJ; Fredenburgh JC; Weitz JI
J Biol Chem; 1998 Jul; 273(29):18292-9. PubMed ID: 9660794
[TBL] [Abstract][Full Text] [Related]
23. Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other.
Litvinov RI; Yakovlev S; Tsurupa G; Gorkun OV; Medved L; Weisel JW
Biochemistry; 2007 Aug; 46(31):9133-42. PubMed ID: 17630702
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Hancock MA; Boffa MB; Marcovina SM; Nesheim ME; Koschinsky ML
J Biol Chem; 2003 Jun; 278(26):23260-9. PubMed ID: 12697748
[TBL] [Abstract][Full Text] [Related]
25. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.
Sangrar W; Gabel BR; Boffa MB; Walker JB; Hancock MA; Marcovina SM; Horrevoets AJ; Nesheim ME; Koschinsky ML
Biochemistry; 1997 Aug; 36(34):10353-63. PubMed ID: 9265615
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
Sangrar W; Koschinsky ML
Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
[TBL] [Abstract][Full Text] [Related]
29. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen).
Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA
J Biol Chem; 2000 Aug; 275(32):24915-20. PubMed ID: 10816585
[TBL] [Abstract][Full Text] [Related]
30. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation.
Feric NT; Boffa MB; Johnston SM; Koschinsky ML
J Thromb Haemost; 2008 Dec; 6(12):2113-20. PubMed ID: 18983515
[TBL] [Abstract][Full Text] [Related]
31. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a).
Ernst A; Helmhold M; Brunner C; Pethö-Schramm A; Armstrong VW; Müller HJ
J Biol Chem; 1995 Mar; 270(11):6227-34. PubMed ID: 7890760
[TBL] [Abstract][Full Text] [Related]
32. Location of plasminogen-binding sites in human fibrin(ogen).
Váradi A; Patthy L
Biochemistry; 1983 May; 22(10):2440-6. PubMed ID: 6222763
[TBL] [Abstract][Full Text] [Related]
33. Interaction of the fibronectin COOH-terminal Fib-2 regions with fibrin: further characterization and localization of the Fib-2-binding sites.
Makogonenko E; Ingham KC; Medved L
Biochemistry; 2007 May; 46(18):5418-26. PubMed ID: 17425334
[TBL] [Abstract][Full Text] [Related]
34. Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation.
Becker L; Cook PM; Koschinsky ML
Biochemistry; 2004 Aug; 43(31):9978-88. PubMed ID: 15287725
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein(a), fibrin binding, and plasminogen activation.
Loscalzo J; Weinfeld M; Fless GM; Scanu AM
Arteriosclerosis; 1990; 10(2):240-5. PubMed ID: 2138452
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding.
Huby T; Schröder W; Doucet C; Chapman J; Thillet J
Biochemistry; 1995 Jun; 34(22):7385-93. PubMed ID: 7779780
[TBL] [Abstract][Full Text] [Related]
37. Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation.
Bobbink IW; Tekelenburg WL; Sixma JJ; de Boer HC; Banga JD; de Groot PG
Biochem Biophys Res Commun; 1997 Nov; 240(3):595-601. PubMed ID: 9398610
[TBL] [Abstract][Full Text] [Related]
38. Factor XIIIa incorporates thymosin beta4 preferentially into the fibrin(ogen) alphaC-domains.
Makogonenko E; Goldstein AL; Bishop PD; Medved L
Biochemistry; 2004 Aug; 43(33):10748-56. PubMed ID: 15311936
[TBL] [Abstract][Full Text] [Related]
39. The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions.
D'Angelo A; Geroldi D; Hancock MA; Valtulina V; Cornaglia AI; Spencer CA; Emanuele E; Calligaro A; Koschinsky ML; Speziale P; Visai L
Biochim Biophys Acta; 2005 Feb; 1687(1-3):1-10. PubMed ID: 15708348
[TBL] [Abstract][Full Text] [Related]
40. Fibrinogen alpha C domains contain cryptic plasminogen and tPA binding sites.
Tsurupa G; Medved L
Ann N Y Acad Sci; 2001; 936():328-30. PubMed ID: 11460488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
